Next-Generation Sequencing (NGS) in lung cancer care: Advantages, applications, and challenges
DOI:
https://doi.org/10.32932/gecp.2023.12.047Keywords:
Next-Generation Sequencing (NGS), Predictive biomarkers, Lung cancer, Liquid biopsiesAbstract
Lung cancer, a prevalent and lethal malignancy, has witnessed significant therapeutic strides driven by the identification and application of predictive biomarkers. These biomarkers, such as EGFR mutations and ALK rearrangements, guide treatment decisions and improve patient outcomes. The advent of Next-Generation Sequencing (NGS) has revolutionized lung cancer diagnostics and treatment by enabling comprehensive genomic profiling. NGS, a high-throughput sequencing technology, stands out by simultaneously analyzing multiple genes and addressing the genetic diversity inherent in lung tumors. This article explores the transformative role of NGS in lung cancer, emphasizing its applications in personalized treatment strategies, early detection, immunotherapy selection, and disease monitoring through liquid biopsies. Despite challenges, NGS emerges as a beacon of hope, propelling precision oncology and promising improved patient outcomes. This article underscores the impact of NGS in reshaping the landscape of lung cancer care, guiding therapeutic decisions, and advancing scientific understanding.
Downloads
References
Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(4):339-57. Epub 20230123. doi: 10.1016/j.annonc.2022.12.009.
Gridelli C, Rossi A, Carbone DP, Guarize J, Karachaliou N, Mok T, et al. Non-small-cell lung cancer. Nat Rev Dis Primers. 2015;1:15009. Epub 20150521. doi: 10.1038/nrdp.2015.9.
Kim SW, Roh J, Park CS. Immunohistochemistry for Pathologists: Protocols, Pitfalls, and Tips. J Pathol Transl Med. 2016;50(6):411-8. Epub 20161013. doi: 10.4132/jptm.2016.08.08.
Inamura K. Update on Immunohistochemistry for the Diagnosis of Lung Cancer. Cancers (Basel). 2018;10(3). Epub 20180314. doi: 10.3390/cancers10030072.
HuL,RuK,ZhangL,HuangY,ZhuX,LiuH,etal. Fluorescence in situ hybridization (FISH): an increasingly demanded tool for biomarker research and personalized medicine. Biomark Res. 2014;2(1):3. Epub 20140205. doi: 10.1186/2050-7771-2-3.
Isla D, Lozano MD, Paz-Ares L, Salas C, de Castro J, Conde E, et al. New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clin Transl Oncol. 2023;25(5):1252-67. Epub 20221226. doi: 10.1007/ s12094-022-03046-9.
Goswami RS. PCR Techniques in Next-Generation Sequencing. Methods Mol Biol. 2016;1392:143-51. doi: 10.1007/978-1-4939-3360-0_13.
Slatko BE, Gardner AF, Ausubel FM. Overview of Next-Generation Sequencing Technologies. Curr Protoc Mol Biol. 2018;122(1):e59. doi: 10.1002/ cpmb.59.
Kerr KM, Bibeau F, Thunnissen E, Botling J, Ryška A, Wolf J, et al. The evolving landscape of biomarker testing for non-small cell lung cancer in Europe. Lung Cancer. 2021;154:161-75. Epub 20210222. doi: 10.1016/j.lungcan.2021.02.026.
Zou D, Ye W, Hess LM, Bhandari NR, Ale-Ali A, Foster J, et al. Diagnostic Value and Cost-Effectiveness of Next-Generation Sequencing-Based Testing for Treatment of Patients with Advanced/Metastatic Non-Squamous Non-Small-Cell Lung Cancer in the United States. J Mol Diagn. 2022;24(8):901-14. Epub 20220607. doi: 10.1016/j.jmoldx.2022.04.010.
Jennings LJ, Arcila ME, Corless C, Kamel-Reid S, Lubin IM, Pfeifer J, et al. Guidelines for Validation of Next-Generation Sequencing-Based Oncology Panels: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists. J Mol Diagn. 2017;19(3):341-65. Epub 20170321. doi: 10.1016/j. jmoldx.2017.01.011.
LahiriA,MajiA,PotdarPD,SinghN,ParikhP,Bisht B, et al. Lung cancer immunotherapy: progress, pitfalls, and promises. Mol Cancer. 2023;22(1):40. Epub 20230221. doi: 10.1186/s12943-023-01740-y.
Waqar SN, Govindan R. The Mystic Role of Tumor Mutational Burden in Selecting Patients With Lung Cancer for First-Line Immunotherapy. JAMA Oncol. 2020;6(5):674-5. doi: 10.1001/jamaoncol. 2020.0264.
Marcus L, Fashoyin-Aje LA, Donoghue M, Yuan M, Rodriguez L, Gallagher PS, et al. FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid Tumors. Clin Cancer Res. 2021;27(17):4685-9. Epub 20210603. doi: 10.1158/1078-0432.ccr-21-0327.
Lone SN, Nisar S, Masoodi T, Singh M, Rizwan A, Hashem S, et al. Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments. Mol Cancer. 2022;21(1):79. Epub 20220318. doi: 10.1186/s12943-022-01543-7.
Plackett B. How liquid biopsies allow smarter lung-cancer treatment. Nature. 2020;587(7834):S18-S19. doi: 10.1038/d41586-020-03156-w.
LiW,LiuJB,HouLK,YuF,ZhangJ,WuW,etal. Liquid biopsy in lung cancer: significance in diagnostics, prediction, and treatment monitoring. Mol Cancer. 2022;21(1):25. Epub 20220120. doi: 10.1186/s12943-022-01505-z.
Saman H, Raza A, Patil K, Uddin S, Crnogorac-Jurcevic T. Non-Invasive Biomarkers for Early Lung Cancer Detection. Cancers (Basel). 2022;14(23). Epub 20221124. doi: 10.3390/cancers14235782.
Dama E, Colangelo T, Fina E, Cremonesi M, Kallikourdis M, Veronesi G, et al. Biomarkers and Lung Cancer Early Detection: State of the Art. Cancers (Basel). 2021;13(15). Epub 20210803. doi: 10.3390/ cancers13153919.
